DAX23.238 +0,6%Est505.528 +0,2%MSCI World4.343 -0,1%Top 10 Crypto11,67 +3,4%Nas22.581 +1,4%Bitcoin74.581 -1,1%Euro1,1534 +0,2%Öl62,61 +0,2%Gold4.078 +0,3%
Beliebte Suche
DAX 40 Ölpreis Euro - Dollar Bitcoin - Euro Goldpreis
Meistgesucht
Rheinmetall 703000 Bayer BAY001 NVIDIA 918422 Novo Nordisk A3EU6F RENK RENK73 DroneShield A2DMAA Siemens Energy ENER6Y Lufthansa 823212 Deutsche Telekom 555750 HENSOLDT HAG000 TKMS thyssenkrupp Marine Systems TKMS00 Alphabet A (ex Google) A14Y6F BASF BASF11 Amazon 906866 Allianz 840400
Alle Aktien für 0 Euro (zzgl. Spreads) handeln mit finanzen.net zero. Hier informieren
Heute im Fokus
DAX höher -- Wall Street fester erwartet -- Novo Nordisk scheitert bei Alzheimer-Studie -- Alphabet, TKMS, D-Wave, DroneShield, Siemens Energy, Rheinmetall & Co., DHL, Bayer, Lufthansa, NEL im Fokus
Top News
Kraken-Aktie soll kommen: Börsengang der Kryptobörse rückt wohl näher Kraken-Aktie soll kommen: Börsengang der Kryptobörse rückt wohl näher
finanzen.net bewerten & 500€ gewinnen finanzen.net bewerten & 500€ gewinnen
Suche...
Login
ODER

Neu auf finanzen.net?

Kostenfrei registrieren und Vorteile nutzen

Übersicht Wertpapierdepots Musterdepots Watchlists Meine News Newsletter Forum Trading Desk Apps Social Media Podcasts
Profil

Amgen Aktie

Kaufen
Verkaufen
Amgen Aktien-Sparplan
290,30 EUR -5,75 EUR -1,94 %
STU
337,96 USD +0,47 USD +0,14 %
BTT
Amgen jetzt ohne Ordergebühren (zzgl. Spreads) handeln beim ‘Kostensieger’ finanzen.net zero (Stiftung Warentest 11/2024)
Smartphone

Marktkap.157,82 Mrd. EUR

KGV34,48Div. Rendite3,45%
WKN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

WKN867900

ISIN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

ISINUS0311621009

Symbol wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

SymbolAMGN

Amgen Aktien News

DatumMeistgelesen
PR NewswireAMGEN TO PRESENT AT GOLDMAN SACHS 45TH ANNUAL GLOBAL HEALTHCARE CONFERENCE
PR NewswireAMGEN ANNOUNCES POSITIVE RESULTS FOR PHASE 3 REGISTRATIONAL TRIAL EVALUATING UPLIZNA® (INEBILIZUMAB-CDON) FOR TREATMENT OF IMMUNOGLOBULIN G4-RELATED DISEASE (IgG4-RD)
PR NewswireAMGEN TO PRESENT AT JEFFERIES GLOBAL HEALTHCARE CONFERENCE
PR NewswireAMGEN TO PRESENT INNOVATIVE RESEARCH FROM ITS ROBUST ONCOLOGY PORTFOLIO AT ASCO 2024
PR NewswireFDA APPROVES IMDELLTRA™ (TARLATAMAB-DLLE), THE FIRST AND ONLY T-CELL ENGAGER THERAPY FOR THE TREATMENT OF EXTENSIVE-STAGE SMALL CELL LUNG CANCER
PR NewswireAMGEN TO HOST CONFERENCE CALL FOLLOWING ATS 2024
PR NewswireAMGEN TO PRESENT AT THE BANK OF AMERICA MERRILL LYNCH GLOBAL HEALTHCARE CONFERENCE
PR NewswireAMGEN REPORTS FIRST QUARTER 2024 FINANCIAL RESULTS
PR NewswireAMGEN HIGHLIGHTS NEW COPD, ASTHMA AND VASCULITIS RESEARCH AT ATS 2024
PR NewswireAMGEN ANNOUNCES WEBCAST OF 2024 FIRST QUARTER FINANCIAL RESULTS
PR NewswireAMGEN TO SUBMIT TEPROTUMUMAB MARKETING AUTHORIZATION APPLICATION TO THE EUROPEAN MEDICINES AGENCY
PR NewswireAMGEN TO PRESENT TEZSPIRE® PHASE 2A COPD DATA AT ATS 2024
PR NewswireAMGEN PRESENTS NEW RESEARCH ON OTEZLA® (APREMILAST) AT AAD 2024
PR NewswireAMGEN ANNOUNCES 2024 SECOND QUARTER DIVIDEND
PR NewswireAMGEN TO PRESENT AT THE 44TH ANNUAL TD COWEN HEALTH CARE CONFERENCE
PR NewswireAMGEN OPENS STATE-OF-THE-ART BIOMANUFACTURING SITE IN CENTRAL OHIO
PR NewswireAMGEN TO HOST CONFERENCE CALL ON RARE DISEASE
PR NewswireAMGEN TO PRESENT AT THE 34TH ANNUAL OPPENHEIMER HEALTHCARE LIFE SCIENCES CONFERENCE
PR NewswireAMGEN ANNOUNCES WEBCAST OF 2023 FOURTH QUARTER AND FULL YEAR FINANCIAL RESULTS
PR NewswireAMGEN TO PRESENT AT THE 42ND ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE
PR NewswireAMGEN PROVIDES REGULATORY UPDATE ON STATUS OF LUMAKRAS® (SOTORASIB)
PR NewswireAMGEN ANNOUNCES EXECUTIVE APPOINTMENTS TO ACCELERATE INNOVATION
PR NewswireAMGEN TO SPONSOR THE IRISH OPEN
PR NewswireFDA Grants Priority Review to Amgen's Tarlatamab Application for Advanced Small Cell Lung Cancer
PR NewswireAMGEN ANNOUNCES 2024 FIRST QUARTER DIVIDEND INCREASE TO $2.25 PER SHARE
PR NewswireAMGEN HIGHLIGHTS HEMATOLOGY PORTFOLIO AT ASH 2023
PR NewswireAMGEN TO PRESENT AT THE EVERCORE ISI HEALTHCONX CONFERENCE
PR NewswireAMGEN PRESENTS NEW CARDIOVASCULAR RESEARCH AT AHA 2023
PR NewswireAMGEN PRESENTS NEW RESEARCH IN EARLY PSORIATIC ARTHRITIS AT ACR 2023
PR NewswireAMGEN PRESENTS NEW DATA FROM PHASE 2 TRIAL OF DAZODALIBEP IN SJÖGREN'S SYNDROME AT ACR 2023
PR NewswireEpidemiology and Genetics of Clonal Hematopoiesis, a Premalignant Hematopoietic Stem Cell Condition
PR NewswireEpidemiology and Genetics of Clonal Hematopoiesis, a Premalignant Hematopoietic Stem Cell Condition
PR NewswireEpidemiology and Genetics of Clonal Hematopoiesis, a Premalignant Hematopoietic Stem Cell Condition
PR NewswireEpidemiology and Genetics of Clonal Hematopoiesis, a Premalignant Hematopoietic Stem Cell Condition
PR NewswireAMGEN PRESENTS NEW DATA THAT SHOW BLOOD PRESSURE DECREASES FOR ADULTS TREATED WITH KRYSTEXXA® (PEGLOTICASE)
PR NewswireAMGEN TO PRESENT DATA AT ACR 2023 ACROSS EXPANDED RHEUMATOLOGY PIPELINE AND PORTFOLIO
PR NewswireAMGEN ANNOUNCES WEBCAST OF 2023 THIRD QUARTER FINANCIAL RESULTS
PR NewswireAMGEN ANNOUNCES 2023 FOURTH QUARTER DIVIDEND
PR NewswireAMGEN PRESENTS NEW LUMAKRAS® (SOTORASIB) PLUS VECTIBIX® (PANITUMUMAB) DATA IN PATIENTS WITH KRAS G12C-MUTATED METASTATIC COLORECTAL CANCER
PR NewswireAMGEN PRESENTS NEW TARLATAMAB DATA IN SMALL CELL LUNG CANCER

Amgen News

Amgen News: auf dieser Seite finden Sie alle Amgen News und Nachrichten zur Amgen Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Amgen News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Amgen News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.